文献速递心脑血管急症消化、代谢与肾脏急症

白细胞介素-1β抑制(卡那奴单抗)对动脉粥样硬化患者肺癌发生率的影响:随机双盲安慰剂对照试验的探索性结果

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet · 2017-08-27
一句话结论CANTOS探索性分析显示,卡那奴单抗300 mg每3月皮下注射可降低动脉粥样硬化患者肺癌发生率(HR 0·33)和肺癌死亡率(HR 0·23),但致命感染或脓毒症显著增加。

CANTOS试验在10061例有心梗史、无既往癌症诊断且hsCRP≥2 mg/L的动脉粥样硬化患者中,随机给予卡那奴单抗50 mg、150 mg、300 mg皮下注射每3月或安慰剂。中位随访3.7年,卡那奴单抗呈剂量依赖性降低hsCRP 26-41%和IL-6 25-43%。肺癌发生率在150 mg组(HR 0·61)和300 mg组(HR 0·33)显著降低,肺癌死亡率在300 mg组显著降低(HR 0·23)。总癌症死亡率在汇总卡那奴单抗组显著低于安慰剂组,但仅300 mg组单独显著(HR 0·49)。致命感染或脓毒症在卡那奴单抗组显著更常见,全因死亡率无显著差异。作者认为该假设生成数据提示靶向IL-1β固有免疫通路可能减少肺癌发生和死亡,需在正式癌症筛查和治疗环境中重复验证。

要点

  • 在10061例有心梗史、无既往癌症且hsCRP≥2 mg/L的动脉粥样硬化患者中,卡那奴单抗300 mg皮下注射每3月使肺癌发生率显著降低(HR 0·33 [95%CI 0·18-0·59])。
  • 卡那奴单抗300 mg组肺癌死亡率显著低于安慰剂组(HR 0·23 [95%CI 0·10-0·54]),150 mg组肺癌发生率亦显著降低(HR 0·61 [95%CI 0·39-0·97])。
  • 总癌症死亡率在汇总卡那奴单抗组显著低于安慰剂组(趋势p=0·0007),但仅300 mg组单独显著(HR 0·49 [95%CI 0·31-0·75])。
  • 致命感染或脓毒症在卡那奴单抗组显著多于安慰剂组;全因死亡率无显著差异(HR 0·94 [95%CI 0·83-1·06])。
  • 作者认为该假设生成数据提示抗IL-1β治疗可能减少肺癌发生和死亡,但需在正式癌症筛查和治疗环境中重复验证。

适用人群与场景

  • 动脉粥样硬化患者,有心梗史,无既往癌症诊断,hsCRP≥2 mg/L。

诊断标准与关键阈值

  • 入组要求hsCRP≥2 mg/L;基线hsCRP中位6·0 mg/L(后续诊断肺癌者)vs 4·2 mg/L(未诊断癌症者),p<0·0001;基线IL-6 3·2 vs 2·6 ng/L,p<0·0001。

处置流程与药物剂量

  • 卡那奴单抗50 mg、150 mg或300 mg皮下注射,每3月一次,随机分配;对照为安慰剂。

红旗征与不能漏的情况

  • 致命感染或脓毒症在卡那奴单抗组显著多于安慰剂组。

研究设计与关键结果

  • 随机双盲安慰剂对照试验(CANTOS),10061例动脉粥样硬化患者,随机分至卡那奴单抗50 mg、150 mg、300 mg皮下注射每3月或安慰剂;中位随访3.7年。
  • 卡那奴单抗呈剂量依赖性降低hsCRP 26-41%和IL-6 25-43%(所有比较p<0·0001)。
  • 肺癌发生(n=129)在150 mg组(HR 0·61 [95%CI 0·39-0·97];p=0·034)和300 mg组(HR 0·33 [95%CI 0·18-0·59];p<0·0001;组间趋势p<0·0001)显著少于安慰剂组。
  • 肺癌死亡率在300 mg组显著低于安慰剂组(HR 0·23 [95%CI 0·10-0·54];p=0·0002),汇总卡那奴单抗组趋势p=0·0002。
  • 总癌症死亡(n=196)在汇总卡那奴单抗组显著低于安慰剂组(趋势p=0·0007),仅300 mg组单独显著(HR 0·49 [95%CI 0·31-0·75];p=0·0009)。
  • 全因死亡率在卡那奴单抗组与安慰剂组无显著差异(HR 0·94 [95%CI 0·83-1·06];p=0·31)。

证据类型、等级与局限

  • 证据类型:随机双盲安慰剂对照试验的探索性分析(CANTOS),注册号NCT01327846,试验已关闭(末次患者访视2017年6月)。
  • 局限:作者称该数据为假设生成性,需在正式癌症筛查和治疗环境中重复验证。

对床旁实践的改变

  • 作者认为靶向IL-1β固有免疫通路的抗炎治疗可能显著减少肺癌发生和肺癌死亡,但需在正式癌症筛查和治疗环境中重复验证。
  • 在动脉粥样硬化患者中使用卡那奴单抗时,需注意致命感染或脓毒症在卡那奴单抗组显著更常见。

指南或共识出处

  • CANTOS试验(Canakinumab Anti-inflammatory Thrombosis Outcomes Study),ClinicalTrials.gov NCT01327846;资助方Novartis Pharmaceuticals。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomised trial of the role of interleukin-1β inhibition in atherosclerosis, with the aim of establishing whether inhibition of a major product of the Nod-like receptor protein 3 (NLRP3) inflammasome with canakinumab might alter cancer incidence.

METHODS: We did a randomised, double-blind, placebo-controlled trial of canakinumab in 10 061 patients with atherosclerosis who had had a myocardial infarction, were free of previously diagnosed cancer, and had concentrations of high-sensitivity C-reactive protein (hsCRP) of 2 mg/L or greater. To assess dose-response effects, patients were randomly assigned by computer-generated codes to three canakinumab doses (50 mg, 150 mg, and 300 mg, subcutaneously every 3 months) or placebo. Participants were followed up for incident cancer diagnoses, which were adjudicated by an oncology endpoint committee masked to drug or dose allocation. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, NCT01327846. The trial is closed (the last patient visit was in June, 2017).

FINDINGS: Baseline concentrations of hsCRP (median 6·0 mg/L vs 4·2 mg/L; p<0·0001) and interleukin 6 (3·2 vs 2·6 ng/L; p<0·0001) were significantly higher among participants subsequently diagnosed with lung cancer than among those not diagnosed with cancer. During median follow-up of 3·7 years, compared with placebo, canakinumab was associated with dose-dependent reductions in concentrations of hsCRP of 26-41% and of interleukin 6 of 25-43% (p<0·0001 for all comparisons). Total cancer mortality (n=196) was significantly lower in the pooled canakinumab group than in the placebo group (p=0·0007 for trend across groups), but was significantly lower than placebo only in the 300 mg group individually (hazard ratio [HR] 0·49 [95% CI 0·31-0·75]; p=0·0009). Incident lung cancer (n=129) was significantly less frequent in the 150 mg (HR 0·61 [95% CI 0·39-0·97]; p=0·034) and 300 mg groups (HR 0·33 [95% CI 0·18-0·59]; p<0·0001; p<0·0001 for trend across groups). Lung cancer mortality was significantly less common in the canakinumab 300 mg group than in the placebo group (HR 0·23 [95% CI 0·10-0·54]; p=0·0002) and in the pooled canakinumab population than in the placebo group (p=0·0002 for trend across groups). Fatal infections or sepsis were significantly more common in the canakinumab groups than in the placebo group. All-cause mortality did not differ significantly between the canakinumab and placebo groups (HR 0·94 [95% CI 0·83-1·06]; p=0·31).

INTERPRETATION: Our hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality. Replication of these data in formal settings of cancer screening and treatment is required.

FUNDING: Novartis Pharmaceuticals.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017. PMID: 28855077. doi:10.1016/S0140-6736(17)32247-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。